13+ hour, 21+ min ago  (190+ words) Johnson & Johnson's Phase 3 PROTEUS study shows ERLEADA (apalutamide) combined with hormone therapy before and after surgery significantly improves outcomes for high-risk localized prostate cancer patients. The treatment increased the chance of minimal cancer remaining at surgery by nine times and…...

13+ hour, 21+ min ago  (290+ words) Immatics presented Phase 1 clinical trial data for its IMA401 TCR bispecific targeting MAGEA4/8, showing durable responses and good tolerability in heavily pretreated solid tumor patients, including melanoma and head and neck cancer. The data, also published in Nature Medicine, support combining IMA401 with…...

13+ hour, 21+ min ago  (487+ words) Eli Lilly announced that the Phase 3 LIBRETTO-432 trial of Retevmo (selpercatinib) significantly improved event-free survival by reducing the risk of recurrence or death by 83% compared to placebo in early-stage RET fusion-positive non-small cell lung cancer patients. This is the first…...

13+ hour, 21+ min ago  (279+ words) Immunocore announced updated Phase 1/2 data for brenetafusp in heavily pretreated advanced melanoma patients, showing a 6-month overall survival rate of 87% and a disease control rate of 52%. The 160 mcg dose demonstrated better clinical outcomes and will be used in the ongoing…...

13+ hour, 21+ min ago  (292+ words) Johnson & Johnson's Phase 3 PROTEUS study found that combining apalutamide with hormone therapy before and after prostate cancer surgery significantly improves outcomes for high-risk localized or locally advanced prostate cancer patients. The treatment made patients nine times more likely to have…...

13+ hour, 21+ min ago  (293+ words) Ivonescimab, an experimental lung cancer drug developed by Akeso and Summit Therapeutics, improved overall survival by 34% in a Phase 3 trial conducted in China, extending median survival by four months compared to standard immunotherapy plus chemotherapy. The drug targets PD-1 and…...

13+ hour, 21+ min ago  (367+ words) Novartis announced that Pluvicto combined with standard care significantly improves radiographic progression-free survival (r PFS) in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (m HSPC), regardless of disease volume or presentation. The Phase 3 PSMAddition trial showed a 28% reduction in risk…...

1+ day, 13+ hour ago  (278+ words) The Pompa Program, a wellness coaching service focused on addressing cellular inflammation and chronic health issues, has surpassed 1, 300 verified Trustpilot reviews, maintaining a high average rating of 4. 7 out of 5 stars. This milestone highlights the program's effectiveness in helping participants overcome…...

1+ day, 13+ hour ago  (237+ words) Sichuan Kelun-Biotech announced positive Phase III trial results for sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab as first-line treatment for PD-L1 positive non-small cell lung cancer (NSCLC). The combination significantly extended progression-free survival and showed a positive trend in overall survival…...

1+ day, 13+ hour ago  (209+ words) Bio NTech and Bristol Myers Squibb announced encouraging interim Phase 2 results for pumitamig, a PD-L1x VEGF-A bispecific immunomodulator, combined with chemotherapy in untreated advanced non-small cell lung cancer (NSCLC). The ROSETTA Lung-02 trial showed high confirmed objective response rates across…...